Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides

Antisense oligonucleotides (oligos) have been employed against in vivo and in vitro prostate cancer models targeting growth regulatory proteins. In LNCaP cells, we evaluated both monospecific and bispecific oligos that targeted and comparably suppressed the expression of bcl-2, an apoptosis inhibito...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2012-09, Vol.29 (3), p.2284-2290
Main Authors: Rubenstein, Marvin, Hollowell, Courtney M. P., Guinan, Patrick
Format: Article
Language:English
Subjects:
Adaptations
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Genes, bcl-2 - drug effects
Hematology
Humans
Insulin-Like Growth Factor I - biosynthesis
Interleukin-4 - biosynthesis
Internal Medicine
Male
Medicine
Medicine & Public Health
Oligonucleotides, Antisense - pharmacology
Oncology
Original Paper
Pathology
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors
Receptors, Androgen - biosynthesis
Reverse Transcriptase Polymerase Chain Reaction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antisense oligonucleotides (oligos) have been employed against in vivo and in vitro prostate cancer models targeting growth regulatory proteins. In LNCaP cells, we evaluated both monospecific and bispecific oligos that targeted and comparably suppressed the expression of bcl-2, an apoptosis inhibitory protein. Cells compensated with both suppressed caspase-3 (an apoptosis promoter) activity, and an enhancement of both androgen receptor (AR) and p300 expression. This suggests that a progression to increased androgen sensitivity accompanies bcl-2 suppression, in this tumor line. To further evaluate mechanisms of adaptation, we now evaluate the effects upon the expression of insulin-like growth factor (IGF1) and another AR coactivator, IL-4, thought to increase prostate cancer growth. IGF1 expression was not significantly altered suggesting this pathway need not be regulated when bcl-2 directed gene therapy is employed. In contrast to increased AR and p300 expression that compensated for bcl-2 suppression, the AR coactivator IL-4 expression was not increased, suggesting no role in any increased androgen sensitivity.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-011-0097-4